Clinical outcomes of a 3-day modified BEP regimen in malignant ovarian germ cell tumors in a single-center real-world study
Open Access
- 10 June 2026
- journal article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
Abstract
Malignant ovarian germ cell tumors (MOGCTs) mainly affect adolescents and young women and are highly curable with bleomycin, etoposide, and cisplatin (BEP). To reduce toxicity associated with the standard 5-day regimen, we evaluated the efficacy, safety, and fertility outcomes of a 3-day modified BEP regimen in patients with MOGCTs. We conducted a retrospective analysis of 81 MOGCT patients with 3-day modified BEP at the Women's Hospital, Zhejiang University School of Medicine from 2004 to 2024. The 3-day modified BEP regimen comprised bleomycin (15 U) and etoposide (100 mg/m2) on days 1-3, and cisplatin (75 mg/m2) on day 1, repeated every 4 weeks for 3-6 cycles. All 81 MOGCT patients included in our study underwent primary surgery before chemotherapy; 86.4% had early-stage disease, and fertility-sparing surgery was performed in 73 cases. After a median follow-up of over 9 years, the 5-year progression-free survival rate was 97.5% (95% CI: 94.2-100), with no treatment-related deaths. Bleomycin-induced pneumonitis occurred in 4.9% and resolved with supportive care. Among 30 patients attempting conception, 90% achieved pregnancy, resulting in 25 term live births. The 3-day modified BEP regimen provides excellent survival with reduced toxicity, offering greater convenience and preserved fertility, supporting its use as a safer and more practical treatment alternative for initial chemotherapy in MOGCTs.Keywords
Funding Information
- Women's Hospital, Zhejiang University School of Medicine
- National Natural Science Foundation of China
This publication has 30 references indexed in Scilit:
- Neuroendocrine-associated epigenetic factors in cellular senescence: mechanisms and therapeutic implicationsBiogerontology, 2026
- A maturing approach to the assessment of ovarian teratomasBest Practice & Research Clinical Obstetrics & Gynaecology, 2026
- KDM1A Facilitates Oncogenic Potential in Colorectal Cancer Progression Through the Activation of AXIN/GSK3β/β‐Catenin Signaling Pathways: Evidence From Integrated Transcriptomics and In Vitro StudiesThe Journal of Gene Medicine, 2025
- Machine learning-driven multimodal optimization of selenium biotransformation and flavor profiling in fermented apple–Yacon functional beveragesInnovative Food Science & Emerging Technologies, 2025
- Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practiceEuropean Journal of Cancer, 2020
- Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989–2015European Journal of Cancer, 2019
- Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter studyAmerican Journal of Obstetrics and Gynecology, 2018
- Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978–2010)European Journal of Cancer, 2014
- Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancerCancer, 2010
- Favorable Outcome of Ovarian Germ Cell Malignancies Treated with Cisplatin or Carboplatin-Based Chemotherapy: A Hellenic Cooperative Oncology Group StudyGynecologic Oncology, 1998